New Enhancing CLIA Act: What Lab Directors Need to Know
The proposal seeks to move any future LDT authority away from the FDA
Already a member? Log in here
FDA-nir
Subscribe today for access to
Articles and Reports
FDA Watch: Natera, Valar Labs Receive FDA Clearances for Bladder Cancer Tests
Natera’s assay focuses on the need for adjuvant therapy, while Valar’s test stratifies risk of recurrence
Already a member? Log in here
FDA Watch: New RAPID Coverage Pathway Would Enable Some Lab Tests to Pursue Clearance and Medicare Coverage Simultaneously
FDA-CMS collaboration aims to accelerate Medicare coverage determinations of certain medical devices
Already a member? Log in here
EBOLA Continues to Warrant Attention From Labs
...
Already a member? Log in here
ACLA Issues White Paper Arguing Against FDA Regulation of LDT
...
Already a member? Log in here
- « Previous
- 1
- …
- 17
- 18
- 19